The Frontotemporal Dementia (FTD) drugs in development market research report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Frontotemporal Dementia (FTD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Frontotemporal Dementia (FTD) and features dormant and discontinued products.
GlobalData tracks 93 drugs in development for Frontotemporal Dementia (FTD) by 82 companies/universities/institutes. The top development phase for Frontotemporal Dementia (FTD) is preclinical with 54 drugs in that stage. The Frontotemporal Dementia (FTD) pipeline has 88 drugs in development by companies and five by universities/ institutes. Some of the companies in the Frontotemporal Dementia (FTD) pipeline products market are: P2D, Crucible Therapeutics and AviadoBio.
The key targets in the Frontotemporal Dementia (FTD) pipeline products market include TAR DNA Binding Protein 43, Microtubule Associated Protein Tau, and Guanine Nucleotide Exchange C9orf72.
The key mechanisms of action in the Frontotemporal Dementia (FTD) pipeline product include Microtubule Associated Protein Tau Inhibitor with seven drugs in Phase I. The Frontotemporal Dementia (FTD) pipeline products include 11 routes of administration with the top ROA being Oral and 15 key molecule types in the Frontotemporal Dementia (FTD) pipeline products market including Small Molecule, and Gene Therapy.
Frontotemporal Dementia (FTD) overview
Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD’s exact cause remains unclear, but abnormal protein deposits in the brain are implicated. Diagnosis involves medical history, exams, imaging, and neuropsychological tests. Unfortunately, no cure exists, but treatments focus on symptom management and enhancing quality of life. Tailored support from healthcare professionals and caregivers is pivotal in addressing FTD’s diverse and challenging impacts.
For a complete picture of Frontotemporal Dementia (FTD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
